Your browser is no longer supported. Please, upgrade your browser.
ORMP [NASD]
Oramed Pharmaceuticals Inc.
Index- P/E- EPS (ttm)-0.71 Insider Own10.24% Shs Outstand29.93M Perf Week-1.46%
Market Cap418.46M Forward P/E- EPS next Y-0.83 Insider Trans0.00% Shs Float29.42M Perf Month6.05%
Income-18.40M PEG- EPS next Q-0.38 Inst Own10.20% Short Float7.62% Perf Quarter33.11%
Sales2.70M P/S154.99 EPS this Y31.80% Inst Trans8.55% Short Ratio4.00 Perf Half Y95.45%
Book/sh2.28 P/B6.22 EPS next Y-21.40% ROA-32.30% Target Price22.50 Perf Year269.53%
Cash/sh2.36 P/C6.01 EPS next 5Y- ROE-41.20% 52W Range2.40 - 16.63 Perf YTD234.67%
Dividend- P/FCF- EPS past 5Y3.50% ROI-35.70% 52W High-14.67% Beta1.92
Dividend %- Quick Ratio12.60 Sales past 5Y- Gross Margin- 52W Low491.25% ATR1.22
Employees12 Current Ratio12.60 Sales Q/Q0.00% Oper. Margin- RSI (14)54.35 Volatility13.23% 9.01%
OptionableYes Debt/Eq0.00 EPS Q/Q-76.80% Profit Margin- Rel Volume0.86 Prev Close14.58
ShortableYes LT Debt/Eq0.00 Earnings- Payout- Avg Volume560.89K Price14.19
Recom1.60 SMA207.26% SMA508.79% SMA20069.63% Volume480,909 Change-2.67%
Apr-20-21Initiated Canaccord Genuity Buy $27
Feb-09-21Initiated National Securities Buy
Dec-03-20Initiated Alliance Global Partners Buy $11
Mar-11-20Initiated Aegis Capital Buy $5.50
Sep-11-19Initiated Ladenburg Thalmann Buy $7
Dec-11-17Resumed B. Riley FBR, Inc. Buy $20
May-26-16Reiterated FBR Capital Outperform $15 → $20
Dec-01-15Reiterated H.C. Wainwright Buy $24 → $25
Nov-19-15Initiated FBR Capital Outperform $15
Apr-13-15Resumed MLV & Co Buy $27 → $30
Jan-30-14Reiterated Aegis Capital Buy $30 → $35
Jan-08-14Reiterated Aegis Capital Buy $25 → $30
Jan-08-14Initiated MLV & Co Buy $27
Dec-03-13Initiated Aegis Capital Buy $25
Jul-29-21 08:25AM  
Jul-21-21 11:44AM  
08:25AM  
Jul-19-21 07:18AM  
Jun-22-21 11:22AM  
08:40AM  
Jun-18-21 12:52PM  
Jun-08-21 08:10AM  
May-25-21 08:40AM  
Apr-21-21 07:25AM  
Apr-19-21 09:56AM  
Mar-25-21 11:46AM  
11:20AM  
09:20AM  
Mar-23-21 08:51AM  
Mar-19-21 10:30AM  
09:34AM  
08:40AM  
Mar-16-21 08:25AM  
Mar-04-21 08:25AM  
Jan-27-21 09:00AM  
Jan-21-21 08:25AM  
Jan-08-21 05:19AM  
Jan-07-21 08:40AM  
Dec-23-20 08:25AM  
Dec-10-20 08:05AM  
Dec-03-20 09:05PM  
Dec-02-20 08:25AM  
Nov-24-20 08:10AM  
Nov-12-20 08:40AM  
Nov-10-20 08:25AM  
Nov-09-20 12:26PM  
Oct-28-20 08:40AM  
Oct-27-20 08:55AM  
Oct-16-20 08:40AM  
Sep-22-20 07:12AM  
Sep-21-20 08:25AM  
Sep-15-20 08:25AM  
Sep-03-20 08:10AM  
Aug-11-20 12:20PM  
Jul-16-20 10:19AM  
Jul-15-20 08:55AM  
Jul-08-20 06:09PM  
Jun-19-20 05:34AM  
Jun-15-20 08:25AM  
Jun-09-20 07:03AM  
Jun-04-20 06:59PM  
May-05-20 09:22AM  
07:55AM  
Apr-14-20 07:10AM  
Apr-07-20 07:40AM  
Apr-01-20 08:40AM  
Mar-30-20 09:01AM  
Mar-19-20 08:40AM  
Mar-11-20 06:30AM  
Feb-27-20 09:15AM  
07:35AM  
Feb-26-20 04:05PM  
08:00AM  
Feb-12-20 09:42AM  
Feb-04-20 08:25AM  
Jan-30-20 07:25AM  
Jan-28-20 07:25AM  
Jan-23-20 08:00AM  
Jan-21-20 07:25AM  
Jan-09-20 07:00AM  
Jan-07-20 11:38AM  
08:00AM  
Dec-22-19 06:17PM  
Dec-05-19 09:12AM  
Dec-02-19 09:16AM  
08:25AM  
Nov-25-19 09:57AM  
Nov-21-19 08:27AM  
Nov-19-19 08:55AM  
Nov-14-19 07:28AM  
Nov-12-19 07:00AM  
Oct-21-19 03:06PM  
Sep-20-19 12:20PM  
Sep-18-19 08:38AM  
Sep-17-19 08:40AM  
Sep-03-19 08:25AM  
Aug-16-19 08:31AM  
Aug-05-19 04:05PM  
Jul-11-19 12:28PM  
Jul-10-19 08:40AM  
Jul-02-19 08:25AM  
Jun-25-19 10:50AM  
Jun-18-19 08:40AM  
Jun-03-19 09:25AM  
May-21-19 08:55AM  
May-07-19 04:15PM  
Apr-29-19 08:25AM  
Apr-28-19 09:47AM  
Apr-11-19 08:55AM  
Apr-04-19 08:55AM  
Apr-03-19 08:55AM  
Mar-28-19 08:40AM  
Mar-26-19 08:40AM  
Feb-06-19 02:31PM  
Oramed Pharmaceuticals Inc. engages in the research and development of pharmaceutical solutions for the treatment of diabetes and for the use of orally ingestible capsules or pills for delivery of polypeptides. Its proprietary flagship product is the ORMD-0801, an orally ingestible insulin capsule, which completed phase II clinical trials for the treatment of individuals with diabetes. It is also developing ORMD-0901, an oral glucagon-like peptide-1 capsule that has completed phase I clinical trials for the treatment of type 2 diabetes; and a weight loss treatment in the form of an oral leptin capsule. The company was formerly known as Integrated Security Technologies, Inc. and changed its name to Oramed Pharmaceuticals Inc. in April 2006. Oramed Pharmaceuticals Inc. was founded in 2002 and is based in New York, New York.